Prakash K Pandalai
Overview
Explore the profile of Prakash K Pandalai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jain A, Schultz K, Brainerd M, Murimwa G, Fleming A, Fackche N, et al.
Ann Surg Oncol
. 2024 Sep;
31(13):9112.
PMID: 39313730
No abstract available.
2.
Jain A, Schultz K, Brainerd M, Murimwa G, Fleming A, Fackche N, et al.
Ann Surg Oncol
. 2024 Aug;
31(13):9100-9111.
PMID: 39138773
Social media has become omnipresent in society, especially given that it enables the rapid and widespread communication of news, events, and information. Social media platforms have become increasingly used by...
3.
McDonald H, Kennedy A, Solomon A, Williams C, Reagan A, Cassim E, et al.
Ann Surg Oncol
. 2024 Aug;
31(12):7705-7712.
PMID: 39133448
Background: Guidelines now recommend universal germline genetic testing (GGT) for all pancreatic ductal adenocarcinoma (PDAC) patients. Testing provides information on actionable pathogenic variants and guides management of patients and family....
4.
McDonald H, Zaki O, Wright M, Jayswal R, Weiss H, Nair R, et al.
Ann Surg Oncol
. 2023 Nov;
31(2):1252-1263.
PMID: 38006531
Background: Discontinuation of the Codman 3000 pump in 2018 left no Food and Drug Administration (FDA)-approved hepatic artery infusion (HAI) device for unresectable colorectal liver metastases (uCLM) and intrahepatic cholangiocarcinoma...
5.
Estock J, Pandalai P, Johanning J, Youk A, Varley P, Arya S, et al.
J Surg Res
. 2023 Aug;
292:130-136.
PMID: 37619497
Introduction: The Risk Analysis Index (RAI) is a frailty assessment tool associated with adverse postoperative outcomes including 180 and 365-d mortality. However, the RAI has been criticized for only containing...
6.
McDonald H, Sarvestani A, Owen J, Rueckert J, Wierman M, Kiseljak-Vassiliades K, et al.
HPB (Oxford)
. 2023 Jul;
25(11):1446-1449.
PMID: 37453816
No abstract available.
7.
van Reesema L, Hutchcraft M, Freidberg N, Graves J, Tovar M, Pandalai P, et al.
Gynecol Oncol Rep
. 2023 May;
47:101198.
PMID: 37251788
•Pelvic SFTs are rare, typically benign soft tissue neoplasms that pose a diagnostic challenge for gynecologists.•Retroperitoneal pelvic SFTs can mimic gynecologic malignancies and should be considered in diagnosis of a...
8.
McDonald H, Patel R, Ellis C, Gholami S, Barry-Hundeyin M, Pandalai P, et al.
Surgery
. 2023 May;
174(1):101-105.
PMID: 37137740
Implementation of a successful hepatic artery infusion pump program requires numerous factors to be in place, and the lack of any of these may lead to program failure. First and...
9.
McDonald H, Cassim E, Harper M, Burke E, Marcinkowski E, Cavnar M, et al.
Surg Oncol Clin N Am
. 2022 Nov;
32(1):13-25.
PMID: 36410913
Investigator-initiated trials (IITs) are designed by principal investigators who identify important, unaddressed clinical gaps and opportunities to answer these questions through clinical trials. Surgical oncologists are poised to lead IITs...
10.
Choi M, Harper M, Pandalai P, Abdel-Misih S, Patel R, Ellis C, et al.
Ann Surg Oncol
. 2022 Nov;
30(2):804-813.
PMID: 36344711
Background: Nanoliposomal irinotecan (nal-IRI) is a promising novel hyperthermic intraperitoneal chemotherapy (HIPEC) agent given its enhanced efficacy against gastrointestinal tumors, safety profile, thermo-synergy, and heat stability. This report describes the...